Point Therapeutics to Present Novel Dual Mechanism of Action for Talabostat During Research and Development Day on April 25; Ne
April 18 2006 - 7:22AM
Business Wire
Point Therapeutics, Inc. (NASDAQ:POTP) announced it will
comprehensively review the novel dual mechanism of action for its
lead compound, talabostat, a targeted anti-cancer therapy. For the
first time, Point will unveil the identified targets and cellular
biochemistry responsible for talabostat's anti-tumor activity. The
dual mechanism of action is based talabostat's inhibition of
fibroblast activation protein (FAP) inhibition and talabostat's
immunostimulatory properties. The R&D Day will be at the Four
Seasons New York on April 25, 2006 from 4:30 to 6:30 pm ET. The
event will feature a scientific overview of talabostat by Dr. Barry
Jones, Chief Scientific Officer at Point Therapeutics, and Dr.
Charles Dinarello, Professor of Medicine, University of Colorado
School of Medicine, who will review the peer-reviewed data
available about the compound and its mechanism of action. "We are
pleased to have an opportunity to comprehensively present
talabostat's mechanism of action during our upcoming R&D Day.
Our extensive preclinical studies support an exciting, novel dual
mechanism of action for talabostat. These studies are the
foundation of talabostat's clinical program, which includes two
Phase 3 studies in non-small cell lung cancer and ongoing Phase 2
studies in metastatic melanoma, chronic lymphocytic leukemia and
pancreatic cancer," said Don Kiepert, President and CEO of Point
Therapeutics. For reservations, please contact Sarah Cavanaugh at
617-933-7508 or scavanaugh@pther.com. About Point Therapeutics,
Inc.: Point is a Boston-based biopharmaceutical company developing
a portfolio of dipeptidyl peptidase (DPP) inhibitors for use in
cancer, type 2 diabetes and as vaccine adjuvants. Point is
currently studying its lead product candidate, talabostat, in two
Phase 3 trials in non-small cell lung cancer. Point is also
studying talabostat in several Phase 2 trials, including as a
single-agent in metastatic melanoma, in combination with cisplatin
in metastatic melanoma, in combination with rituximab in advanced
chronic lymphocytic leukemia, and in combination with gemcitabine
in metastatic pancreatic cancer. In addition, Point's portfolio
includes two other DPP inhibitors in preclinical
development--PT-630 for type 2 diabetes, and PT-510 as a vaccine
adjuvant. Certain statements contained herein are not strictly
historical and are "forward looking" statements as defined in the
Private Securities Litigation Reform Act of 1995. This information
includes statements with respect to the company's clinical
development programs and the timing of initiation and completion of
its clinical trials. Forward-looking statements are statements that
are not historical facts, and can be identified by, among other
things, the use of forward-looking language, such as "believes,"
"feels," "expects," "may," "will," "should," "seeks," "plans,"
"schedule to," "anticipates" or "intends" or the negative of those
terms, or other variations of those terms of comparable language,
or by discussions of strategy or intentions. A number of important
factors could cause actual results to differ materially from those
projected or suggested in the forward looking statement, including
the risk factors described in Point's quarterly report on Form 10-K
for the year ended December 31, 2005 and from time to time in
Point's periodic and other reports filed with the Securities and
Exchange Commission.
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Point Therapeutics (MM) (NASDAQ): 0 recent articles
More Point Therapeutics, Inc. News Articles